Proximity labeling (PL) has, in recent years, evolved from a “tool for studying protein interactions” into a method for elucidating… Proximity proteome, subcellular microenvironment, dynamic signal transduction, and drug mechanisms of action An important technological platform. Technologies such as TurboID, miniTurbo, BioID2, APEX2, AirID, and Split-TurboID have been continuously refined, enabling researchers to label proteins within a defined spatial vicinity of a target protein in living cells, and further combine this approach with mass spectrometry (LC‑MS/MS) to generate proximity‑dependent proteomic profiles.

 

However, in actual projects, The success or failure of proximity-labeling experiments often depends on more than just “which enzyme to choose.” 。

 

The structure of the target protein, the position of the tag, the linker length, the expression level, cellular localization, substrate‑processing time, control design, and the subsequent mass‑spectrometry workflow all influence the final results. Therefore, when undertaking projects to generate proximity‑labeling cell lines, LIMAN Bio places particular emphasis on starting from “ Target protein—tag—cell line—validation—mass spectrometry “The entire link is designed.”

 

Building on Q&A 1.0, this article further compiles advanced issues that clients frequently encounter during the construction of proximity‑labeling experiments.

Service Guide | Comprehensive Q&A on the Construction of Stable Cell Lines Using Proximity Labeling Technology [Version 2511]

 

Q1: Why do different target proteins yield vastly different results when using TurboID?

This is a very common issue in proximity‑labeling experiments. While TurboID itself exhibits high biotinylation efficiency, the resulting proximity profile depends not only on TurboID activity but also on factors such as the target protein’s expression level, its subcellular localization, the orientation of the TurboID fusion, linker length, the spatial relationship between TurboID and the target protein, the duration of biotinylation, the cell type, the background level of biotinylation, and the design of control conditions.

 

Therefore, high TurboID activity does not mean that all proteins are suitable for direct use as TurboID C‑terminal fusions. For example: for Membrane protein , the position of the intracellular domain needs to be considered; for Secretory protein , it is necessary to consider the subcellular localization following entry into the ER–secretory pathway; for Nucleoprotein , it is necessary to consider whether the nuclear localization signal is affected by the tag; for Protein complex , it is also necessary to consider whether the label affects protein assembly.

 

Therefore, prior to formal protein engineering, it is recommended to first perform structural and subcellular localization analyses of the target protein.

 

Q2: If the target protein is expressed at very low levels, is it still suitable for performing in situ TurboID–knock-in experiments?

 

Yes, but it requires careful evaluation. The primary advantage of in situ KI is its ability to maintain target protein expression at levels close to endogenous levels, thereby enhancing physiological relevance.

 

However, if the target protein itself exhibits extremely low endogenous expression, rapid turnover, expression only under specific stimuli, or is present exclusively in a small subset of cells, then even with successful KI, the neighboring labeling signal may remain weak.

 

In this situation, you may consider:

Option A: Endogenous TurboID-KI : Suitable for studies that emphasize physiological relevance.

Option B: Stable low-level OE : Enhance detection sensitivity while minimizing expression levels as much as possible.

Option C: OE as the POC → KI as the final validation

 

First, verify whether the target protein can be effectively proximity‑labeled, and then proceed to generate an in situ KI cell line.

 

Therefore, “low endogenous expression” does not mean that KI cannot be performed; rather, it requires striking a balance between physiological relevance and assay sensitivity.

 

Q3: Does the proximity marker necessarily have to be generated as a monoclonal cell line?

Not necessarily. Depending on the project’s objectives, you can choose:

① The stable pool is suitable for POC, rapid validation, preliminary mass spectrometry, and tag‑configuration screening, among other applications. Its main advantage is a shorter turnaround time, helping to avoid prematurely moving into large‑scale monoclonal screening.

② Monoclonal cell lines are suitable for long-term use, repeated mass spectrometry experiments, studies of drug mechanisms, in situ KI, and projects with stringent requirements for expression levels and genotypes.

③ In situ KI monoclonal: If the project emphasizes physiological conditions, in situ KI monoclonals are typically given priority.

 

In practical projects, it is advisable to proceed step by step—starting with a stable pool, followed by functional validation, single‑clone isolation, and finally deep mass spectrometry—rather than jumping straight into complex single‑clone screening.

 

Q4: Should the proximity labeling tag be placed at the N-terminus or the C-terminus?

 

This is a critically important issue in cell line design; it cannot be simply stipulated that “TurboID must be fused to the C-terminus.” Instead, the decision must be made in conjunction with the structure of the target protein.

More inclined toward consumer‑end integration. Examples of such cases include: the N‑terminus contains a signal peptide; the N‑terminus mediates membrane localization; the N‑terminus harbors an important functional domain; or the N‑terminus carries a critical post‑translational modification site.

More likely to undergo N-terminal fusion such as: the C‑terminal harbors critical functional domains; the C‑terminal contains localization signals; the C‑terminal participates in protein–protein interactions; and the C‑terminal exerts important regulatory functions.

 

If both the N‑terminal and C‑terminal regions harbor potential functional risks, consider constructing the N‑terminal and C‑terminal variants in parallel.

 

For critical projects, this approach is generally more reliable than “building a single version and then having to rework it if functional issues arise.”

 

Q5: How important is the linker, exactly? Why do proximity labels often require a linker to be designed?

Linker is not merely a “connecting sequence.” It influences: the spatial distance between the tag and the target protein; the spatial accessibility of TurboID/APEX2; the folding of the target protein; the assembly of protein complexes; and the extent of contact between the tagging enzyme and neighboring proteins.

 

Therefore, in many cases, a flexible linker—such as (GGGGS)n—can be employed to confer a degree of conformational freedom to the neighboring labeling enzyme. However, longer linkers are not necessarily better; excessive length may increase the range of tag conformational fluctuations, promote non-specific proximity labeling, and interfere with protein structure.

 

Therefore, in practical design, it is necessary to comprehensively determine the approach based on the target protein’s structure, subcellular localization, and the position of the tag.

 

Q6: When performing proximity labeling of membrane proteins, what specific considerations should be taken into account?

 

Membrane proteins are a very common target for proximity labeling, and they also present several potential pitfalls.

 

First, it is necessary to clarify: which side of the membrane protein is TurboID located on?

For example, a typical transmembrane protein: Extracellular | TM | Intracellular

• If you wish to study the protein neighborhood on the cytoplasmic side, TurboID must be localized to the cytoplasm.
• If the tag is mistakenly placed on the extracellular side, the resulting product may consist primarily of proteins adjacent to the extracellular/membrane‑outer surface, rather than the intended cytoplasmic signaling network.

 

For multi-transmembrane proteins and GPCRs, further analysis is required, including the orientation of the N- and C-termini, intracellular loops, extracellular loops, key phosphorylation sites, protein endocytosis motifs, and regions involved in G‑protein or arrestin binding.

 

Therefore, for membrane proteins, the “tag orientation” itself is an integral part of the experimental design.

 

Q7: How should one design TurboID proximity labeling for GPCRs?

GPCRs are a relatively typical example of complex targets. Typically, one can consider the following based on the research objective:

 

Option 1: Consumer-Side TurboID

Suitable for research on: β-arrestin–related proteins, cytoplasmic signaling proteins, endocytosis‑related proteins, and proximity‑based protein changes following GPCR activation.

 

Option 2: N-terminal TurboID

Particular attention should be paid to the signal peptide, receptor maturation, and the extracellular domain.

 

Option 3: Pre- and Post-Stimulation Comparison

For example: Vehicle group vs Ligand group

Further analysis: What changes occur in the neighboring protein repertoire from the pre‑activated state to the post‑activated state of the GPCR?

For drug discovery projects, this dynamic proximity‑omics approach is particularly valuable.

 

Q8: If the target protein is a secreted protein, can TurboID still be used?

 

Yes, but the experimental system will need to be reconsidered.

 

Secreted proteins typically follow the pathway: ER → Golgi → Secretory pathway → Extracellular. If TurboID is directly fused to a secreted protein, TurboID may traverse the corresponding secretory pathway.

 

At this stage, it is essential to carefully evaluate the signal peptide, the ER environment, disulfide bond formation, protein folding, Golgi processing, and the activity of TurboID within the relevant cellular compartment. Consequently, the TurboID experimental design used for cytoplasmic proteins cannot be applied indiscriminately.

 

For secreted proteins, it is advisable to determine, based on the research objective, whether the focus should be on the pre-secretory processing pathway, the proteins adjacent to the secretion pathway, or the extracellular microenvironment; different objectives call for distinct construct‑design strategies.

 

Q9: If the target protein is very small, for example only 10–20 kDa, is it still suitable for TurboID fusion?

 

This is a critical issue that warrants careful pre‑evaluation: TurboID itself has a molecular mass of approximately 35 kDa. If the target protein is only 15 kDa, then upon fusion—resulting in TurboID plus the target protein—the tag could end up being several times larger than the target protein alone.

 

At this stage, key considerations include protein folding, subcellular localization, protein stability, existing interactions, and functional domains. In particular, for compact small proteins, it is advisable not to judge solely on the basis of “whether fusion is feasible,” but rather to assess whether the fused construct retains full functional integrity as the target protein.

 

When necessary, comparisons can be made among N‑terminal TurboID, C‑terminal TurboID, smaller tags such as miniTurbo and APEX2, or other suitable small‑size labeling systems.

 

Q10: Can proximity labeling directly demonstrate that two proteins physically interact?

 

They cannot be equated; proximity labeling detects proximity—i.e., spatial closeness—rather than direct physical interaction—i.e., direct physical binding.

 

Therefore, the proteins identified by mass spectrometry may include: direct interactors, proteins belonging to the same complex, proteins localized to the same subcellular compartment, proteins that transiently associate with the target protein, or proteins involved in the same signaling pathway.

 

Therefore, a more precise formulation would be “candidate neighboring proteins,” rather than simply referring to them as “directly interacting proteins.”

 

If direct interaction needs to be demonstrated, additional assays such as co‑IP, pull‑down, PLA, FRET/BRET, and purified protein‑binding experiments can be employed for validation.

 

Q11: If the target protein harbors disease‑associated mutations, can proximity labeling be performed?

 

Yes, and it is highly informative. For example, one could construct WT‑Target‑TurboID and Mutant‑Target‑TurboID constructs and compare them in the same cellular context, thereby investigating whether the mutation alters the neighboring protein network surrounding the target protein.

 

Furthermore, one can analyze: newly acquired neighboring proteins, lost neighboring proteins, alterations in signaling pathways, changes in subcellular localization, and modifications in protein complexes.

 

This design is particularly well suited for studying disease mechanisms and validating therapeutic targets.

 

Q12: If the subcellular localization of a TurboID‑fused protein is abnormal, what should be done?

First, do not proceed directly to mass spectrometry; we recommend troubleshooting in the following order:

① Label orientation: N-terminus vs C-terminus.

② Linker: Adjust the linker’s length or structure.

③ Tag type: TurboID → miniTurbo / APEX2, etc.

④ Expression level: Overexpression may lead to aberrant localization.

⑤ Cellular background: Different cell types exhibit varying degrees of tolerance to fusion proteins.

⑥ Reconfirm the localization of the target protein itself: avoid mistaking the aberrant localization of a fusion protein for the native localization of the target protein.

 

Therefore, when a localization defect is detected, prioritize optimizing the construction strategy rather than simply increasing expression levels.

 

Conclusion

 

The true value of proximity labeling lies in more than simply “biotinylating nearby proteins.” A high‑quality proximity‑labeling experiment requires simultaneous consideration of: the target protein’s properties, tag selection, fusion orientation, linker design, expression level, cellular context, experimental controls, labeling conditions, and mass‑spectrometry strategy. Any one of these components, if poorly designed, can compromise the resulting proximal proteome profile.

 

Therefore, for the construction of proximity‑labeling cell lines, “expression” is only the first step; a truly functional proximity‑labeling cell line must also exhibit correct subcellular localization, normal cellular function, effective labeling, controllable background signals, and compatibility with downstream mass spectrometry analysis.

 

Liman Bio offers a comprehensive solution—tailored to diverse target proteins and research objectives—that encompasses label‑tagging strategy design, stable overexpression, CRISPR‑mediated in situ knock-in, monoclonal cell line screening, cell line quality control, as well as proximity labeling validation and downstream mass spectrometry analysis.

 

If you are planning a project involving TurboID, APEX2, BioID2, miniTurbo, AirID, or Split-TurboID, you can evaluate your experimental design based on the target protein’s gene or protein name, cell line, tag type, N‑ or C‑terminal requirements, and downstream experimental objectives.